Why isn’t there more clinical evidence on HBOT?
Some say it’s because investigators find it difficult to design good experiments with double-blinded study and control groups. Others say it’s because there’s no deep-pocket pharmaceutical company or government agency to fund expensive human clinical trials on HBOT. We say it’s also because the healthcare consumer and patient advocate groups have not been given a loud enough voice.
